Literature DB >> 22966397

Nodal metastasis in well-differentiated follicular carcinoma of the thyroid: Its incidence and clinical significance.

Mitsuyoshi Hirokawa1, Yasuhiro Ito, Seiji Kuma, Yuuki Takamura, Akihiro Miya, Kaoru Kobayashi, Akira Miyauchi.   

Abstract

The clinical significance of nodal metastasis in well-differentiated follicular carcinoma (WD-FC) of the thyroid remains a controversial issue. This study aimed to clarify clinical and pathological characteristics of WD-FC with nodal metastasis, based on the new WHO classification. We examined 249 WD-FC cases diagnosed between 1983 and 2004 in our hospital. Poorly differentiated follicular carcinoma was not included in this study. Of the 249 WD-FC cases, 9 (3.6%) revealed nodal metastasis. The incidences of nodal metastasis in minimally invasive and widely invasive cases were 2.0 and 9.8%, respectively. In four patients, nodal metastasis was detected in the ipsilateral lymph nodes during the initial surgery. A total of 6 patients presented with nodal metastasis 2-10 years after the initial operation, and 3 patients with bilateral and large nodal metastases were relatively young. No patients succumbed to the carcinoma. Primary lesions of WD-FC with nodal metastasis were microscopically conventional, and there were no findings predicting nodal metastasis. We hypothesized that the incidence of nodal metastasis in WD-FC, based on the new WHO classification, was lower compared with previous reports. Younger individuals may be at a higher risk of large bilateral nodal metastasis. The presence of nodal metastasis did not affect the long-term outcome of follicular carcinoma.

Entities:  

Year:  2010        PMID: 22966397      PMCID: PMC3436349          DOI: 10.3892/ol_00000154

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  19 in total

Review 1.  Poorly differentiated thyroid carcinoma: introduction to the issue, its landmarks, and clinical impact.

Authors:  Juan Rosai
Journal:  Endocr Pathol       Date:  2004       Impact factor: 3.943

2.  A detailed histological study on occult metastasis of the lymph nodes.

Authors:  S Natsugoe; T Aiko; H Shimazu
Journal:  Jpn J Surg       Date:  1991-09

Review 3.  Role of immunohistochemistry in the diagnosis and progression of follicular epithelium-derived thyroid carcinoma.

Authors:  Sherif Rezk; Ashraf Khan
Journal:  Appl Immunohistochem Mol Morphol       Date:  2005-09

Review 4.  Prognostic variables of papillary and follicular thyroid carcinoma patients with lymph node metastases and without distant metastases.

Authors:  J D Lin; M J Liou; T C Chao; H F Weng; Y S Ho
Journal:  Endocr Relat Cancer       Date:  1999-03       Impact factor: 5.678

5.  Risk factors in follicular thyroid carcinomas. A retrospective follow-up study covering a 14-year period with emphasis on morphological findings.

Authors:  W Lang; H Choritz; H Hundeshagen
Journal:  Am J Surg Pathol       Date:  1986-04       Impact factor: 6.394

Review 6.  Thyroid tumors with a follicular growth pattern: problems in differential diagnosis.

Authors:  Saul Suster
Journal:  Arch Pathol Lab Med       Date:  2006-07       Impact factor: 5.534

Review 7.  Definition of poorly differentiated carcinoma of the thyroid: the Japanese experience.

Authors:  Atsuhiko Sakamoto
Journal:  Endocr Pathol       Date:  2004       Impact factor: 3.943

8.  Insular carcinoma: a distinct de novo entity among follicular carcinomas of the thyroid gland.

Authors:  S Pilotti; P Collini; L Mariani; M Placucci; I Bongarzone; P Vigneri; S Cipriani; F Falcetta; R Miceli; M A Pierotti; F Rilke
Journal:  Am J Surg Pathol       Date:  1997-12       Impact factor: 6.394

9.  Factors influencing the survival of patients with follicular carcinoma of the thyroid gland.

Authors:  G Crile; K I Pontius; W A Hawk
Journal:  Surg Gynecol Obstet       Date:  1985-05

Review 10.  Problems and controversies in the histopathology of thyroid carcinomas of follicular cell origin.

Authors:  Ronald Ghossein
Journal:  Arch Pathol Lab Med       Date:  2009-05       Impact factor: 5.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.